PHB1 and colorectal carcinoma: Analysis of the contents of both malignant and non-malignant CRC EVs derived from patient samples, in the future, would provide additional data for the assessment of EVs as therapeutic agent or for biomarkers (i.e., 14-3-3 and prohibitin) for potential therapeutic targets and drug development for CRC.